Polymer Capital Management HK LTD Grows Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Polymer Capital Management HK LTD grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 33.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,000 shares of the medical research company’s stock after buying an additional 1,249 shares during the quarter. Polymer Capital Management HK LTD’s holdings in Charles River Laboratories International were worth $985,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Cetera Investment Advisers raised its stake in shares of Charles River Laboratories International by 223.4% in the first quarter. Cetera Investment Advisers now owns 9,740 shares of the medical research company’s stock worth $2,639,000 after buying an additional 6,728 shares during the period. Cetera Advisors LLC raised its holdings in shares of Charles River Laboratories International by 197.1% during the 1st quarter. Cetera Advisors LLC now owns 3,357 shares of the medical research company’s stock worth $910,000 after acquiring an additional 2,227 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Charles River Laboratories International by 94.3% in the 2nd quarter. GAMMA Investing LLC now owns 849 shares of the medical research company’s stock valued at $175,000 after acquiring an additional 412 shares during the last quarter. DNB Asset Management AS boosted its stake in Charles River Laboratories International by 16.6% during the second quarter. DNB Asset Management AS now owns 8,383 shares of the medical research company’s stock worth $1,732,000 after buying an additional 1,196 shares during the period. Finally, Park Avenue Securities LLC grew its stake in shares of Charles River Laboratories International by 2.3% during the second quarter. Park Avenue Securities LLC now owns 3,901 shares of the medical research company’s stock valued at $806,000 after buying an additional 86 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRL. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 target price on the stock. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. Baird R W lowered Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 8th. Finally, Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price target for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $214.38.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Trading Down 1.0 %

NYSE:CRL opened at $199.23 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock’s 50 day simple moving average is $194.24 and its 200-day simple moving average is $204.24. Charles River Laboratories International, Inc. has a 12-month low of $176.48 and a 12-month high of $275.00. The firm has a market cap of $10.19 billion, a P/E ratio of 24.93, a PEG ratio of 5.19 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the prior year, the company posted $2.72 earnings per share. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).